info:eu-repo/semantics/article
Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose
Fecha
2021-08Registro en:
Rossi, Andrés Hugo; Ojeda, Diego Sebastian; Varese, Augusto; Sanchez, Lautaro Nicolas; González López Ledesma, María Mora; et al.; Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose; Cell Press; Cell Reports Medicine; 2; 8; 8-2021; 1-16
2666-3791
CONICET Digital
CONICET
Autor
Rossi, Andrés Hugo
Ojeda, Diego Sebastian
Varese, Augusto
Sanchez, Lautaro Nicolas
González López Ledesma, María Mora
Mazzitelli, Ignacio Gabriel
Alvarez Juliá, Anabel
Oviedo Rouco, Santiago
Pallarés, Horacio Martín
Costa Navarro, Guadalupe Soledad
Rasetto, Natalí Belén
Garcia, Corina Ileana
Wenker, Shirley Denise
Ramis, Lila Yanina
Bialer, Magali Graciela
de Leone, María José
Hernando, Carlos Esteban
Sosa, Santiago
Bianchimano, Luciana
Rios, Antonella Soledad
Treffinger Cienfuegos, Maria Soledad
Caramelo, Julio Javier
Longueira, Yesica Soledad
Laufer, Natalia Lorna
Alvarez, Diego Ezequiel
Carradori, Jorge
Pedrozza, Dariana
Rima, Alejandra
Echegoyen, Cecilia
Ercole, Regina
Gelpi, Paula
Marchetti, Susana
Zubieta, Martín
Docena, Guillermo H.
Kreplak, Nicolas
Yanovsky, Marcelo Javier
Geffner, Jorge Raúl
Pifano, Marina
Gamarnik, Andrea Vanesa
Resumen
Massive vaccination offers great promise for halting the global COVID-19 pandemic. However, the limited supply and uneven vaccine distribution create an urgent need to optimize vaccination strategies. We evaluate SARS-CoV-2-specific antibody responses after Sputnik V vaccination of healthcare workers in Argentina, measuring IgG anti-spike titers and neutralizing capacity after one and two doses in a cohort of naive or previously infected volunteers. By 21 days after receiving the first dose of the vaccine, 94% of naive participants develop spike-specific IgG antibodies. A single Sputnik V dose elicits higher antibody levels and virus-neutralizing capacity in previously infected individuals than in naive ones receiving the full two-dose schedule. The high seroconversion rate after a single dose in naive participants suggests a benefit of delaying administration of the second dose to increase the number of people vaccinated. The data presented provide information for guiding public health decisions in light of the current global health emergency.